Journal of Clinical Oncology最新文献

{"title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma.","authors":"Arun Kumar Arunachalam, Cassandra K Gilmour, Jan Joseph Melenhorst","doi":"10.1200/JCO-25-00568","DOIUrl":"10.1200/JCO-25-00568","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2296-2299"},"PeriodicalIF":42.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions.","authors":"Elizabeth K S Barksdale, Wendy Selig, Willyanne DeCormier Plosky, Erin Miller, Keri McDonough, Chelsea Backler, Elizabeth George, Mark E Fleury, Marc J Taylor, Diana E Pankevich, Jim Murphy, Kristin Hermann, Leigh Ann Davis, Gissoo DeCotiis, Cecile Gonzalez-Cerimele, Colleen Cook, Sandra Shaw, Luke Gelinas, Dana L Dornsife, Barbara E Bierer, David E Gerber","doi":"10.1200/JCO-24-01577","DOIUrl":"10.1200/JCO-24-01577","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2231-2238"},"PeriodicalIF":42.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy.","authors":"Jens Hoeppner,Claudia Schmoor,Thomas Brunner,Peter Bronsert,Patrick Sven Plum,Fabian Nimczewski,Zsolt Madarasz,Florian Lordick","doi":"10.1200/jco-25-00948","DOIUrl":"https://doi.org/10.1200/jco-25-00948","url":null,"abstract":"The ESOPEC trial showed that perioperative chemotherapy with fluorouracil (FU)/leucovorin/oxaliplatin/docetaxel (FLOT) improved survival in patients with nonmetastatic esophageal adenocarcinoma compared with preoperative chemoradiotherapy with CROSS (41.4Gy/carboplatin/paclitaxel). For this analysis, patients from the ESOPEC trial who underwent tumor resection were eligible. The reported end points here include cause-specific mortality, recurrence-free survival (RFS), and sites of recurrence. Of the 438 patients enrolled in ESOPEC, 192 of 221 (86.9%) FLOT patients and 179 of 217 (82.5%) CROSS patients underwent tumor resection. After a median follow-up of 56 months, 178 experienced disease recurrence (81 FLOT; 97 CROSS) and 28 died without recurrence (12 FLOT; 16 CROSS). The 3-year RFS rate was 54.5% in FLOT patients versus 39.0% in CROSS patients (hazard ratio [HR], 0.67 [95% CI, 0.51 to 0.89]; P = .005). Locoregional recurrence occurred in 39 FLOT versus 32 CROSS patients (3-year cumulative incidences 20.2% v 17.4%, HR, 1.00 [95% CI, 0.62 to 1.61]; P = .99). Distant recurrence occurred in 64 FLOT versus 89 CROSS patients (3-year cumulative incidences 31.5% v 47.2%, HR, 0.59 [95% CI, 0.43 to 0.82]; P = .002). Compared with CROSS, perioperative chemotherapy with FLOT improved survival through better systemic tumor control with a reduction in distant tumor recurrences, while locoregional efficacy was similar.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"4 1","pages":"JCO2500948"},"PeriodicalIF":45.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.","authors":"Adrian G Sacher,Wilson H Miller,Manish R Patel,Luis Paz-Ares,Armando Santoro,Myung-Ju Ahn,Rafal Dziadziuszko,Pierre Freres,Jia Luo,Samantha Bowyer,Jayesh Desai,Ben Markman,Maria De Miguel,Sanjeev Deva,Alejandro Falcon,Guzman Alonso,João Daniel Guedes,Se Hyun Kim,Matthew G Krebs,Scott A Laurie,Erminia Massarelli,Laura Medina,Hans Prenen,Alessio Amatu,Marloes Van Dongen,Yoonha Choi,Xuefeng Hou,Ting Qi,Mark T Lin,Kalpesh Koli,Mariah C Mayo,Kenneth K Yau,Stephanie Royer-Joo,Julie Chang,Tomi Jun,Neekesh V Dharia,Jennifer L Schutzman,Patricia Lorusso, , ","doi":"10.1200/jco-25-00040","DOIUrl":"https://doi.org/10.1200/jco-25-00040","url":null,"abstract":"Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C-positive non-small cell lung cancer (NSCLC). Here, we report long-term (≥1 year) follow-up of single-agent divarasib from the ongoing, open-label, and multicenter phase I study (ClinicalTrials.gov identifier: NCT04449874). The primary objective was safety, and the other objectives included preliminary antitumor activity. Overall, 65 patients with advanced KRAS G12C-positive NSCLC received single-agent oral divarasib 50-400 mg once daily and 31 patients (48%) were treated beyond 1 year. Divarasib continued to be well tolerated, and the safety profile beyond 1 year was consistent with the overall safety profile. In patients with measurable disease at baseline across all dose levels (n = 63), the confirmed objective response rate was 55.6% (95% CI, 42.5 to 68.1), and the median duration of response was 18.0 months (95% CI, 11.1 to 24.9). The median progression-free survival was 13.8 months (95% CI, 9.8 to 25.4) in the overall population (N = 65) and 15.3 months (95% CI, 12.3 to 26.1) among patients assigned to the 400-mg dose level (n = 44). With extended follow-up, divarasib demonstrated long-term safety and antitumor activity in patients with advanced KRAS G12C-positive NSCLC.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"13 1","pages":"JCO2500040"},"PeriodicalIF":45.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.","authors":"Fedro A Peccatori,Samuel M Niman,Ann H Partridge,Monica Ruggeri,Marco Colleoni,Cristina Saura,Chikako Shimizu,Anna B Satersdal,Judith R Kroep,Karen Gelmon,Frederic Amant,Audrey Mailliez,Halle C F Moore,Manuel Ruiz-Borrego,Janice M Walshe,Virginia F Borges,Andrea Gombos,Akemi Kataoka,Christine Rousset-Jablonski,Simona Borstnar,Junko Takei,Jeong E Lee,Christobel Saunders,Vesna Bjelic-Radisic,Snezana Susnjar,Fatima Cardoso,Natalie J Klar,Teresa Ferreiro,Sarra El-Abed,Martine Piccart,Larissa A Korde,Aron Goldhirsch,Richard D Gelber,Olivia Pagani,Hatem A Azim, ","doi":"10.1200/jco-24-02697","DOIUrl":"https://doi.org/10.1200/jco-24-02697","url":null,"abstract":"PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor-positive (HR+) BC who had a live birth in the POSITIVE trial.PATIENTS AND METHODSPOSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of BC events by breastfeeding status.RESULTSAt a median follow-up of 41 months, 317 patients had at least one live birth and 313 were eligible for this analysis. A total of 196 of 313 (62.6%) patients breastfed. A total of 130 of the 167 women (77.8%) who had breast-conserving surgery breastfed, and 90 of 130 (69.2%) breastfed from the unaffected breast only. Sixty-six of the 146 women (45.2%) who underwent unilateral mastectomy breastfed. The frequency of breastfeeding was higher in women older than 35 years (67.6% v 55.7%) and in those without previous children (66.4% v 48.5%). Over half (103 of 196, 52.6%) of women breastfed their first live birth for >4 months (median 4.4 months; 95% CI, 4.0 to 5.3). The cumulative incidence of a BC event at 24 months from first on-study live birth was 3.6% and 3.1% in the breastfeeding and nonbreastfeeding groups, respectively (0.5% difference; 95% CI, -4.3% to 5.2%).CONCLUSIONIn POSITIVE, two thirds of women who gave birth after BC diagnosis breastfed, mostly for 4 months or more. In early follow-up, we did not observe differences in BC-related events in women who breastfed compared with those who did not. These results are key for women who wish to pursue pregnancy and breastfeeding after BC.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"8 1","pages":"JCO2402697"},"PeriodicalIF":45.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).","authors":"Michael K Wong,Mohammed M Milhem,Joseph J Sacco,Judith Michels,Gino K In,Eva Muñoz Couselo,Dirk Schadendorf,Georgia M Beasley,Jiaxin Niu,Bartosz Chmielowski,Trisha M Wise-Draper,Tawnya Lynn Bowles,Katy K Tsai,Céleste Lebbé,Caroline Gaudy-Marqueste,Mark R Middleton,Aglaia Skolariki,Adel Samson,Jason A Chesney,Ari M VanderWalde,Yousef Zakharia,Kevin J Harrington,Elizabeth Appleton,Praveen K Bommareddy,Junhong Zhu,Marcus Viana,Jeannie W Hou,Robert S Coffin,Caroline Robert","doi":"10.1200/jco-25-01346","DOIUrl":"https://doi.org/10.1200/jco-25-01346","url":null,"abstract":"PURPOSEEffective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is an HSV-1-based oncolytic immunotherapy, here evaluated in combination with nivolumab in anti-PD-1-failed melanoma.PATIENTS AND METHODSPatients had advanced melanoma that had confirmed progression on anti-PD-1 (≥8 weeks, last prior treatment). RP1 was administered intratumorally (≤8 doses, ≤10 mL/dose; additional doses allowed) with nivolumab (≤2 years). The objective response rate (ORR) was assessed by independent central review using Response Evaluation Criteria in Solid Tumors version 1.1.RESULTSOf 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, 65.7% had primary anti-PD-1 resistance, 56.4% were PD-L1 negative, and 46.4% received prior anti-PD-1 and anti-CTLA-4 therapy (43.6% in combination and 2.9% sequentially). Confirmed ORR (95% CI) was 32.9% (25.2%-41.3%; 15.0% complete response). Responses occurred with similar frequency, depth, duration, and kinetics for injected and non-injected, including visceral, lesions. Median (95% CI) duration of response was 33.7 (14.1-not reached) months. Overall survival rates (95% CI) at 1 and 2 years were 75.3% (66.9%-81.9%) and 63.3% (53.6%-71.5%), respectively. Biomarker analysis demonstrated broad immune activation associated with response, including increased CD8+ T-cell infiltration and PD-L1 expression. Treatment-related adverse event rates were 77.1% grade 1/2, 9.3% grade 3, 3.6% grade 4, and no grade 5 events.CONCLUSIONSRP1 combined with nivolumab provided deep and durable systemic responses in patients with anti-PD-1-failed melanoma, including those with poor prognostic factors. The safety profile was favorable, with mostly grade 1/2 adverse events. (Funded by Replimune, Inc.; IGNYTE ClinicalTrials.gov, NCT03767348; EudraCT number, 2016-004548-12).","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"1 1","pages":"101200JCO2501346"},"PeriodicalIF":45.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144586442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.","authors":"Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S Abramson","doi":"10.1200/JCO-25-00399","DOIUrl":"https://doi.org/10.1200/JCO-25-00399","url":null,"abstract":"<p><p>We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 10⁶ chimeric antigen receptor-positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500399"},"PeriodicalIF":42.1,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials.","authors":"Saroj Niraula","doi":"10.1200/JCO-25-00325","DOIUrl":"https://doi.org/10.1200/JCO-25-00325","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500325"},"PeriodicalIF":42.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer.","authors":"Xiao-Jing Li, Guo Yu, Guo-Fu Li","doi":"10.1200/JCO-25-00502","DOIUrl":"https://doi.org/10.1200/JCO-25-00502","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500502"},"PeriodicalIF":42.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.","authors":"Chris Labaki, Eddy Saad, Katrine N Madsen, Charbel Hobeika, Kevin Bi, Michel Alchoueiry, Sabrina Camp, Yue Hou, Ziad Bakouny, Sayed Matar, Nourhan El Ahmar, Jackson Nyman, Long Zhang, Carmen Priolo, Rishabh Rout, Melissa Daou, Damir Khabibullin, Samer Salem, Nicholas Schindler, Renée Maria Saliby, Kevin Meli, J Connor Wells, Erica Pimenta, Kosuke Takemura, Jihye Park, Marc Eid, Karl Semaan, Jingxin Fu, Thomas Denize, Razane El Hajj Chehade, Marc Machaalani, Rashad Nawfal, Wassim Daoud Khatoun, Mustafa Saleh, Jad El Masri, Nina Rossa Haddad, Wenxin Xu, Bradley A McGregor, Michelle S Hirsch, Wanling Xie, Daniel Y C Heng, David F McDermott, Sabina Signoretti, Eliezer M Van Allen, Sachet A Shukla, Toni K Choueiri, Elizabeth P Henske, David A Braun","doi":"10.1200/JCO-25-00234","DOIUrl":"https://doi.org/10.1200/JCO-25-00234","url":null,"abstract":"<p><strong>Purpose: </strong>While immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC (ChRCC) and renal oncocytic tumors remain an unmet clinical and scientific need.</p><p><strong>Methods: </strong>Single-cell transcriptomic and T-cell receptor profiling was performed on tumor and adjacent normal tissue of patients with ChRCC and renal oncocytic neoplasms. Using machine learning, the cellular origin of renal oncocytic neoplasms was evaluated, with analysis of associated oncogenic pathways. Using immunohistochemistry, immune infiltration was analyzed in renal oncocytic neoplasms in comparison with clear cell RCC (ccRCC). Immune checkpoint expression, clonal expansion, and tumor specificity were compared between ChRCC and ccRCC. Using the International Metastatic RCC Database Consortium data set, clinical outcomes of patients with metastatic ChRCC (mChRCC) treated with first-line systemic regimens were compared with those of patients with ccRCC.</p><p><strong>Results: </strong>We validated α-intercalated cells as the cellular origin of renal oncocytic neoplasms. We identified a downregulation of HLA class I molecules with enrichment of potentially targetable pathways including mammalian target of rapamycin and ferroptosis in ChRCC. The tumor microenvironment of ChRCC showed markedly decreased immune infiltration, with a pronounced depletion in tumor-infiltrating CD8⁺ T cells. ChRCC-infiltrating CD8⁺ T cells demonstrated lower immune checkpoint expression, diminished clonal expansion, and decreased tumor specificity. Clinical analysis identified poor survival outcomes selectively among patients with mChRCC treated with immune-based therapies.</p><p><strong>Conclusion: </strong>Immunogenomic analysis of ChRCC revealed profound depletion of T cells, with an immune phenotype marked by a lack of expression of immune checkpoints and poor tumor specificity, suggesting that the few T cells in these tumor types are likely nonspecific bystanders. This immune-cold environment hinders an effective response to immunotherapy and underscores the need for ChRCC-tailored treatments designed to improve tumor-specific T-cell infiltration into the microenvironment.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500234"},"PeriodicalIF":42.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}